What is William Blair's Forecast for Neurogene Q1 Earnings?

Neurogene Inc. (NASDAQ:NGNE - Free Report) - Analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of Neurogene in a research note issued to investors on Tuesday, March 25th. William Blair analyst S. Corwin expects that the company will post earnings per share of ($0.92) for the quarter. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Neurogene's current full-year earnings is ($4.27) per share. William Blair also issued estimates for Neurogene's Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.93) EPS, Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($3.70) EPS and FY2026 earnings at ($4.60) EPS.

Separately, HC Wainwright dropped their price target on Neurogene from $55.00 to $50.00 and set a "buy" rating on the stock in a research report on Tuesday, March 25th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Neurogene has an average rating of "Buy" and an average price target of $59.80.

Neurogene Stock Down 5.3 %

Shares of NGNE traded down $0.81 during mid-day trading on Thursday, reaching $14.52. The company's stock had a trading volume of 98,611 shares, compared to its average volume of 210,041. The company has a market cap of $215.69 million, a price-to-earnings ratio of -3.40 and a beta of 1.01. The business has a fifty day moving average of $16.88 and a 200 day moving average of $28.76. Neurogene has a 1 year low of $13.47 and a 1 year high of $74.49.

Remove Ads

Neurogene (NASDAQ:NGNE - Get Free Report) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.99) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.05. The firm had revenue of $0.93 million during the quarter.

Insider Activity at Neurogene

In other Neurogene news, CFO Christine Mikail Cvijic sold 4,501 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $16.94, for a total value of $76,246.94. Following the completion of the sale, the chief financial officer now directly owns 72,343 shares of the company's stock, valued at $1,225,490.42. The trade was a 5.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 9.92% of the company's stock.

Institutional Investors Weigh In On Neurogene

Large investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. acquired a new stake in shares of Neurogene in the fourth quarter worth about $71,000. China Universal Asset Management Co. Ltd. acquired a new position in Neurogene during the fourth quarter valued at approximately $72,000. Virtus ETF Advisers LLC grew its holdings in Neurogene by 45.1% during the fourth quarter. Virtus ETF Advisers LLC now owns 3,183 shares of the company's stock valued at $73,000 after purchasing an additional 989 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Neurogene by 192.8% in the third quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company's stock valued at $91,000 after purchasing an additional 1,429 shares during the period. Finally, Wells Fargo & Company MN lifted its stake in shares of Neurogene by 34.5% in the fourth quarter. Wells Fargo & Company MN now owns 5,444 shares of the company's stock worth $124,000 after buying an additional 1,397 shares during the last quarter. 52.37% of the stock is currently owned by institutional investors.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.